Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Avadel Pharmaceuticals plc stock logo
AVDL
Avadel Pharmaceuticals
$9.06
-0.8%
$8.32
$6.38
$17.30
$876.46M1.41.23 million shs783,726 shs
Pharvaris stock logo
PHVS
Pharvaris
$15.84
-0.9%
$15.39
$11.51
$25.50
$828.27M-2.8572,867 shs73,135 shs
uniQure stock logo
QURE
uniQure
$15.50
+2.2%
$12.50
$3.73
$19.18
$849.03M0.11.89 million shs1.12 million shs
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
$3.04
+8.2%
$3.21
$2.41
$10.37
$235.65M2.321.07 million shs1.25 million shs
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Avadel Pharmaceuticals plc stock logo
AVDL
Avadel Pharmaceuticals
-0.77%-3.31%+3.31%+14.06%-42.48%
Pharvaris stock logo
PHVS
Pharvaris
-0.94%-8.17%-5.94%+2.46%-21.51%
uniQure stock logo
QURE
uniQure
+2.24%+1.24%+9.31%+32.82%+225.63%
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
+8.19%+3.05%-7.88%-42.53%-60.98%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Avadel Pharmaceuticals plc stock logo
AVDL
Avadel Pharmaceuticals
2.245 of 5 stars
3.51.00.00.03.71.70.6
Pharvaris stock logo
PHVS
Pharvaris
1.553 of 5 stars
3.51.00.00.03.10.80.0
uniQure stock logo
QURE
uniQure
3.4173 of 5 stars
4.52.00.00.03.32.50.6
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
4.2702 of 5 stars
4.64.00.00.03.13.31.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Avadel Pharmaceuticals plc stock logo
AVDL
Avadel Pharmaceuticals
3.00
Buy$19.43114.44% Upside
Pharvaris stock logo
PHVS
Pharvaris
3.00
Buy$40.67156.73% Upside
uniQure stock logo
QURE
uniQure
2.91
Moderate Buy$37.82143.99% Upside
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
3.23
Buy$14.90390.13% Upside

Current Analyst Ratings Breakdown

Latest SLDB, AVDL, PHVS, and QURE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/22/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight$16.00
5/19/2025
uniQure stock logo
QURE
uniQure
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/19/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$16.00 ➝ $15.00
5/16/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$20.00 ➝ $17.00
5/16/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$15.00 ➝ $10.00
5/16/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$18.00 ➝ $17.00
5/14/2025
Pharvaris stock logo
PHVS
Pharvaris
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$28.00 ➝ $25.00
5/13/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/12/2025
uniQure stock logo
QURE
uniQure
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
5/12/2025
uniQure stock logo
QURE
uniQure
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$38.00 ➝ $38.00
5/8/2025
Avadel Pharmaceuticals plc stock logo
AVDL
Avadel Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$19.00 ➝ $19.00
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Avadel Pharmaceuticals plc stock logo
AVDL
Avadel Pharmaceuticals
$194.45M4.51N/AN/A$0.98 per share9.24
Pharvaris stock logo
PHVS
Pharvaris
N/AN/AN/AN/A$7.95 per shareN/A
uniQure stock logo
QURE
uniQure
$20.20M42.03N/AN/A$4.34 per share3.57
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
$8.09M29.13N/AN/A$6.27 per share0.48
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Avadel Pharmaceuticals plc stock logo
AVDL
Avadel Pharmaceuticals
-$160.28M-$0.27N/A151.00N/A-52.53%-93.34%-44.77%8/14/2025 (Estimated)
Pharvaris stock logo
PHVS
Pharvaris
-$109.18M-$3.01N/AN/AN/AN/A-38.52%-36.69%8/13/2025 (Estimated)
uniQure stock logo
QURE
uniQure
-$308.48M-$4.39N/AN/AN/A-837.80%-188.82%-32.17%8/7/2025 (Estimated)
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
-$96.01M-$2.99N/AN/AN/AN/A-58.75%-47.84%8/12/2025 (Estimated)

Latest SLDB, AVDL, PHVS, and QURE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
-$0.53-$0.59-$0.06-$0.59N/AN/A
5/13/2025Q1 2025
Pharvaris stock logo
PHVS
Pharvaris
-$0.80-$0.89-$0.09-$0.89N/AN/A
5/9/2025Q1 2025
uniQure stock logo
QURE
uniQure
-$1.07-$0.82+$0.25-$0.82$5.93 million$1.57 million
5/7/2025Q1 2025
Avadel Pharmaceuticals plc stock logo
AVDL
Avadel Pharmaceuticals
-$0.07-$0.05+$0.02-$0.05$50.57 million$52.51 million
4/7/2025Q4 2024
Pharvaris stock logo
PHVS
Pharvaris
-$0.74-$0.68+$0.06-$0.68N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Avadel Pharmaceuticals plc stock logo
AVDL
Avadel Pharmaceuticals
N/AN/AN/AN/AN/A
Pharvaris stock logo
PHVS
Pharvaris
N/AN/AN/AN/AN/A
uniQure stock logo
QURE
uniQure
N/AN/AN/AN/AN/A
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Avadel Pharmaceuticals plc stock logo
AVDL
Avadel Pharmaceuticals
N/A
2.97
2.60
Pharvaris stock logo
PHVS
Pharvaris
N/A
19.08
19.08
uniQure stock logo
QURE
uniQure
0.92
6.51
6.51
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
N/A
7.85
7.85

Institutional Ownership

CompanyInstitutional Ownership
Avadel Pharmaceuticals plc stock logo
AVDL
Avadel Pharmaceuticals
69.19%
Pharvaris stock logo
PHVS
Pharvaris
N/A
uniQure stock logo
QURE
uniQure
78.83%
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
81.46%

Insider Ownership

CompanyInsider Ownership
Avadel Pharmaceuticals plc stock logo
AVDL
Avadel Pharmaceuticals
4.80%
Pharvaris stock logo
PHVS
Pharvaris
11.84%
uniQure stock logo
QURE
uniQure
4.74%
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
13.63%
CompanyEmployeesShares OutstandingFree FloatOptionable
Avadel Pharmaceuticals plc stock logo
AVDL
Avadel Pharmaceuticals
7096.74 million91.74 millionOptionable
Pharvaris stock logo
PHVS
Pharvaris
3052.29 million46.10 millionNot Optionable
uniQure stock logo
QURE
uniQure
50054.78 million46.43 millionOptionable
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
10077.52 million35.05 millionOptionable

Recent News About These Companies

When Might Solid Biosciences Run Out Of Money?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Avadel Pharmaceuticals stock logo

Avadel Pharmaceuticals NASDAQ:AVDL

$9.06 -0.07 (-0.77%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$9.40 +0.34 (+3.81%)
As of 05:48 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Pharvaris stock logo

Pharvaris NASDAQ:PHVS

$15.99 +0.00 (+0.00%)
As of 05/27/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.

uniQure stock logo

uniQure NASDAQ:QURE

$15.50 +0.34 (+2.24%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$15.48 -0.02 (-0.10%)
As of 05:48 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Solid Biosciences stock logo

Solid Biosciences NASDAQ:SLDB

$3.04 +0.23 (+8.19%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$3.00 -0.04 (-1.45%)
As of 05:55 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.